Lidocaine Patch vs. Diclofenac Gel for Localized PI Pain: A Comparison

James Wong — Founder & Pharmacist, LienScripts | February 12, 2026 | 7 min read

Two leading topical therapies for personal injury pain compared. Understand mechanism differences, neuropathic vs. inflammatory indications, formulations including Ztlido, and pharmacy lien coverage for topical medications.

Topical Analgesia in Personal Injury: Why Localized Therapy Matters

Not all pain after a personal injury is best treated with oral systemic medications. When pain is localized — a neuropathic shoulder, an inflamed knee, a bruised hip — topical analgesics can deliver therapeutic drug concentrations directly to the affected tissue while minimizing systemic exposure and drug interactions. Two topical agents stand out in the PI setting: the lidocaine patch and diclofenac gel.

This article compares these two topical therapies — their mechanisms, indications, formulations, and how pharmacy liens support access to both — to help patients, attorneys, and treating physicians understand which topical is appropriate for which PI injury.

Lidocaine Patch: Mechanism of Action

Lidocaine is a local anesthetic and antiarrhythmic agent that works by blocking voltage-gated sodium channels in nerve cell membranes. When applied topically as a patch, lidocaine diffuses into subcutaneous tissue and perineural structures, stabilizing nerve membranes and reducing the generation and conduction of nerve impulses. This produces localized analgesia — particularly effective for neuropathic pain — without the systemic sedation or opioid-related side effects of oral agents.

The lidocaine patch delivers sustained drug release over the duration of wear (typically 12 hours on, 12 hours off). Because systemic absorption is minimal, lidocaine patches do not produce meaningful blood levels of lidocaine — which means no cardiac or CNS effects from the patch itself, and minimal drug interactions. This safety profile makes lidocaine patches particularly attractive for patients who cannot tolerate oral analgesics or who require additional localized neuropathic pain control layered on top of systemic therapy.

Diclofenac Gel: Mechanism of Action

Diclofenac is a non-selective NSAID that inhibits both COX-1 and COX-2 enzymes, reducing prostaglandin synthesis at sites of inflammation. When formulated as a topical gel, diclofenac penetrates through the skin and accumulates in subcutaneous tissue, synovial fluid, and periarticular structures — achieving therapeutic drug concentrations locally while maintaining lower systemic exposure than oral NSAIDs.

[!SOURCE] Diclofenac topical gel pharmacokinetics: FDA prescribing information for Voltaren Gel (diclofenac sodium 1% topical gel), NDA 022122. Lidocaine patch pharmacokinetics: FDA prescribing information for Lidoderm (lidocaine patch 5%), NDA 020612.

Systemic diclofenac exposure from topical application is approximately 6-10% of the exposure from an equivalent oral dose. This substantially reduced systemic exposure is the key clinical advantage of topical diclofenac over oral NSAIDs — particularly for patients with GI sensitivity, renal concerns, or cardiovascular risk factors that make oral NSAIDs less appropriate.

Indications: Neuropathic vs. Inflammatory Pain

The fundamental clinical distinction between the lidocaine patch and diclofenac gel is the type of pain each is designed to address.

Lidocaine patches are primarily indicated for neuropathic pain — pain arising from damaged or dysfunctional peripheral nerves rather than from tissue inflammation. In PI practice, neuropathic pain commonly occurs after:

• Nerve root compression from herniated disc or spinal stenosis
• Peripheral nerve injury from lacerations or crush injuries
• Post-surgical neuropathic pain syndromes
• Soft tissue entrapment neuropathies
• Post-traumatic complex regional pain syndrome (CRPS)

Diclofenac gel is primarily indicated for inflammatory pain — pain driven by local prostaglandin production at an injury site. In PI practice, appropriate targets include:

• Acute soft tissue injuries (sprains, strains, contusions)
• Osteoarthritis joint pain exacerbated by trauma
• Post-surgical joint inflammation
• Tendinopathy from repetitive strain or direct injury
• Localized musculoskeletal injuries from accident

[!KEY] The choice between a lidocaine patch and diclofenac gel turns on the nature of the pain: neuropathic (nerve-mediated) pain responds better to lidocaine; inflammatory (prostaglandin-mediated) pain responds better to diclofenac. Many PI patients benefit from both, targeting different pain types simultaneously.

Application, Frequency, and Practical Use

Lidocaine patches are typically applied directly to the most painful area of intact skin. The standard protocol is 12 hours on, 12 hours off. Patients apply up to three patches simultaneously to cover larger affected areas. Patches should not be applied over broken skin. The product should not be cut into smaller pieces (though some compounded lidocaine patches are designed differently).

Diclofenac 1% gel (Voltaren prescription strength, or generic) is applied to the affected joint area and rubbed in thoroughly. Application frequency varies by formulation: the 1% gel is typically dosed four times daily to affected joints. Patients are advised to use the lowest effective dose for the shortest necessary duration, consistent with NSAID prescribing principles. Hands must be washed after application unless the hands are the treatment site.

Ztlido vs. Generic Lidocaine Patches

In PI prescribing, two distinct lidocaine patch products are commonly encountered.

Ztlido (lidocaine topical system 1.8%) is a newer formulation that delivers lidocaine through a hydrogel adhesive system. It uses a lower concentration of lidocaine (1.8% vs. 5% in Lidoderm) but achieves equivalent systemic exposure due to its optimized delivery system. Ztlido is often prescribed when improved adhesion or a thinner profile is clinically relevant. As a branded product, it may be covered under a pharmacy lien when prescribed.

Generic lidocaine patch 5% (generic equivalent of Lidoderm) is widely available and commonly dispensed in PI lien programs. It delivers the same therapeutic benefit as the branded Lidoderm at reduced complexity.

Voltaren vs. Prescription Diclofenac 1% Gel

Diclofenac 1% topical gel is now available over the counter as Voltaren Arthritis Pain. The OTC product contains the same active ingredient as the original prescription Voltaren Gel. The key difference in the PI setting:

• OTC Voltaren is available without a prescription and is not covered under a pharmacy lien (which requires a valid prescription)
• Prescription diclofenac 1% gel (either branded or generic) is prescribed by the treating physician and can be covered under a pharmacy lien

For PI patients, having a documented prescription from their treating physician serves multiple purposes: it establishes medical necessity, links the treatment to the injury, and enables pharmacy lien coverage.

When PI Physicians Prescribe Topicals vs. Systemics

Prescribing decisions in PI pain management often involve a layered approach: systemic medications address widespread or severe pain, while topical agents target specific localized areas. Physicians typically prescribe topical agents when:

• Pain is well-localized to a specific joint, nerve distribution, or soft tissue area
• The patient has systemic medication tolerability concerns (GI issues with oral NSAIDs, CNS sensitivity to opioids)
• The patient is already on multiple systemic medications and topicals can reduce the oral medication burden
• A specific neuropathic pain component exists alongside systemic treatment
• Post-surgical wound sites require localized analgesia once healed

Pharmacy Liens Cover Topical Formulations

Both lidocaine patches and prescription diclofenac gel are covered under pharmacy lien programs when prescribed by a licensed provider as part of injury-related care. The lien attaches to the settlement proceeds, with no upfront cost to the patient.

Because topical medications produce a lower systemic drug burden than oral alternatives, they are frequently included in PI treatment plans as part of multimodal analgesia — particularly for patients who require ongoing treatment while minimizing systemic side effects.

Related Resources

• What Is a Pharmacy Lien?
• Flector Patch and Ztlido for Topical Pain in Personal Injury
• Compound Medications in Personal Injury
• Herniated Disc Medications and Pharmacy Lien
• Soft Tissue Injury Medications